Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 67
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Curr Protoc ; 4(3): e938, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38436133

ABSTRACT

The main challenge in the "post-GWAS" era is to determine the functional meaning of genetic variants and their contribution to disease pathogenesis. Development of suitable mouse models is critical because disease susceptibility is triggered by complex interactions between genetic, epigenetic, and environmental factors that cannot be modeled by in vitro models. Thyroglobulin (TG) is a key gene for autoimmune thyroid disease (AITD) and several single nucleotide polymorphisms (SNPs) in the TG coding region have been associated with AITD. The classical model of experimental autoimmune thyroiditis (EAT), based on immunization of genetically susceptible mouse strains with purified TG protein in adjuvant, does not allow testing the impact of TG sequence variants on the development of autoimmune thyroiditis. Here we describe a protocol for the induction of EAT by immunization of mice susceptible to thyroiditis with an adenovirus vector carrying full-length human TG cDNA (Ad-TG EAT). We also provide support protocols for evaluation of autoimmune thyroiditis including serological assessment of TG antibodies, in vitro splenocyte proliferation assay and cytokines secretion, thyroid histology, and evaluation of thyroid lymphocytic infiltration by immunostaining. This protocol for EAT induction allows manipulation of the TG cDNA to introduce variants associated with AITD, enabling the testing of the functional effects of susceptible variants and their haplotypes on the immunogenicity of TG. Furthermore, the Ad-TG EAT mouse model is a valuable model for studying the interactions of the TG variants with non-genetic factors influencing AITD development (e.g., cytokines, iodine exposure) or with variants of other susceptible genes (e.g., HLA-DRß1). © 2024 Wiley Periodicals LLC. Basic Protocol: Development of a mouse model of autoimmune thyroiditis induced by immunization with adenovirus containing full-length thyroglobulin cDNA Support Protocol 1: Splenocytes isolation Support Protocol 2: T cell stimulation and carboxyfluorescein diacetate succinimidyl ester (CFSE) based cell proliferation assay Support Protocol 3: Cytokine assays: measuring levels of interferon gamma (IFNγ) and interleukins IL-2, IL-4, and IL-10 in splenocyte supernatants Support Protocol 4: Evaluating thyroid histology and infiltration with immune cells: hematoxylin-eosin staining of mice thyroid glands Support Protocol 5: Immunohistochemistry of thyroid tissues: Immunofluorescence protocol of paraffin-embedded thyroid sections Support Protocol 6: Anti-thyroglobulin antibody measurement in mice sera by enzyme-linked immunosorbent assay (ELISA).


Subject(s)
Adenoviridae Infections , Hashimoto Disease , Thyroiditis, Autoimmune , Humans , Animals , Mice , Thyroglobulin/genetics , Adenoviridae/genetics , DNA, Complementary/genetics , Immunization , Thyroiditis, Autoimmune/genetics , Cytokines , Disease Models, Animal
2.
J Trace Elem Med Biol ; 79: 127213, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37244045

ABSTRACT

BACKGROUND: Human Adenovirus (HAdV) can cause severe respiratory symptoms in people with low immunity and there is no targeted treatment for adenovirus infection. Anti-adenoviral drugs have high clinical significance for inhibiting adenovirus infection. Selenium (Se) plays an important role in anti-oxidation, redox signal transduction, and redox homeostasis. The excellent biological activity of Se is mainly achieved by being converted into selenocystine (SeC). Se participates in the active sites of various selenoproteins in the form of SeC. The ability of SeC to resist the virus has raised high awareness due to its unique antioxidative activity in recent years. The antiviral ability of the SeC was determined by detecting the infection rate of the virus in the cells. METHODS: The experiment mainly investigated the antiviral mechanism of SeC by locating the virus in the cell, detecting the generation of ROS, observing the DNA status of the cell, and monitoring the mitochondrial membrane potential. RESULTS: In the present study, SeC was designed to resist A549 cells infections caused by HAdV-14. SeC could prevent HAdV-14 from causing cell apoptosis-related to DNA damage. SeC significantly inhibited ROS generation and protect the cells from oxidative damage induced by ROS against HAdV-14. SeC induced the increase of antiviral cytokines such as IL-6 and IL-8 by activating the Jak2 signaling pathway, and repaired DNA lesions by suppressing ATR, p53, and PARP signaling pathways. CONCLUSION: SeC might provide an effective selenium species with antiviral properties for the therapies against HAdV-14.


Subject(s)
Adenoviridae Infections , Adenoviruses, Human , Selenium , Humans , Reactive Oxygen Species/metabolism , Tumor Suppressor Protein p53/metabolism , Poly(ADP-ribose) Polymerase Inhibitors/pharmacology , Adenoviruses, Human/genetics , Selenium/pharmacology , Selenium/metabolism , Apoptosis , Antiviral Agents/pharmacology , Signal Transduction
3.
Planta Med ; 89(10): 1001-1009, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36940926

ABSTRACT

The emergence and re-emergence of viruses has highlighted the need to develop new broad-spectrum antivirals to mitigate human infections. Pursuing our search for new bioactive plant-derived molecules, we study several diterpene derivatives synthesized from jatropholones A and B and carnosic acid isolated from Jatropha isabellei and Rosmarinus officinalis, respectively. Here, we investigate the antiviral effect of the diterpenes against human adenovirus (HAdV-5) that causes several infections for which there is no approved antiviral therapy yet. Ten compounds are evaluated and none of them present cytotoxicity in A549 cells. Only compounds 2, 5 and 9 inhibit HAdV-5 replication in a concentration-dependent manner, without virucidal activity, whereas the antiviral action takes place after virus internalization. The expression of viral proteins E1A and Hexon is strongly inhibited by compounds 2 and 5 and, in a lesser degree, by compound 9. Since compounds 2, 5 and 9 prevent ERK activation, they might exert their antiviral action by interfering in the host cell functions required for virus replication. Besides, the compounds have an anti-inflammatory profile since they significantly inhibit the levels of IL-6 and IL-8 produced by THP-1 cells infected with HAdV-5 or with an adenoviral vector. In conclusion, diterpenes 2, 5 and 9 not only exert antiviral activity against adenovirus but also are able to restrain pro-inflammatory cytokines induced by the virus.


Subject(s)
Adenoviridae Infections , Adenoviruses, Human , Diterpenes , Humans , Antiviral Agents/pharmacology , Adenoviridae , Adenoviruses, Human/metabolism , Diterpenes/pharmacology , Virus Replication
4.
Virology ; 581: 34-38, 2023 04.
Article in English | MEDLINE | ID: mdl-36848735

ABSTRACT

Epidemic keratoconjunctivitis (EKC) is a hazardous and highly contagious disease, with the potential to cause epidemic outbreaks in hospitals and other community settings. There are currently no approved drugs for human adenovirus (HAdV), the causative agent of EKC. To establish a novel drug screening system for ocular HAdV infections, we employed CRL11516, a non-cancerous but immortalized human corneal epithelial cell line. Brincidoforvir and 3'-deoxy-3'-fluorothymidine inhibit replication of HAdV species C type 1 (C1), C2, E4, and C6 to the same extent. This alternative assay system may allow for the evaluation of anti-HAdV activity and cell cytotoxicity of compounds within 2 days and without the need of the rabbit eye infection model.


Subject(s)
Adenoviridae Infections , Adenovirus Infections, Human , Adenoviruses, Human , Keratoconjunctivitis , Animals , Humans , Rabbits , Drug Evaluation, Preclinical , Keratoconjunctivitis/drug therapy , Keratoconjunctivitis/epidemiology , Adenoviridae
5.
Int Ophthalmol ; 42(10): 3221-3228, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35546379

ABSTRACT

PURPOSE: To determine the prevalence of adenoviral conjunctivitis in Turkish ophthalmologists, to provide an overview of the treatment and prophylaxis of adenoviral conjunctivitis, and to analyze the data in the context of evidence-based treatment recommendations. METHODS: An online questionnaire consisting of 20 multiple-choice questions about the characteristics of the respondents, the individual adenoviral conjunctivitis history of the ophthalmologists, their practice's approaches, and prescription preferences were emailed to Turkish ophthalmologists. RESULTS: The survey was emailed to 500 ophthalmologists; 45% of them returned the questionnaire. According to the responses, the history of adenoviral conjunctivitis infections was positive in 46.7% (n: 120), recurrent attack prevalence was 16.2% in ophthalmologists. Lubricants (67.6%) are the most preferred first-line treatment options for adenoviral conjunctivitis, followed by povidone-iodine (59.6%), topical antibiotics (51.1%), topical antivirals (29.3%), topical corticosteroids (26.7%), and topical nonsteroidal anti-inflammatory agents (19.6%). A total of 98.2% preferred to dismiss infected patients. The preferred prophylaxis options were frequent hand washing/use of gloves (97.8%), disinfection of medical devices (95.1%), isolation of infected patients (79.1%), hand hygiene with gemicides (58.7%). The percentage of single-dose eye drop selection was 46.2. CONCLUSIONS: The findings of this survey showed that most Turkish ophthalmologists generally follow international guidelines for the treatment of adenoviral conjunctivitis. The treatment algorithm is still controversial, so ophthalmologists should be aware of treatment guideline updates in line with evidence-based recommendations. Having sufficient knowledge of the basic characteristics of viruses is important to control the spread of the disease.


Subject(s)
Adenoviridae Infections , Conjunctivitis, Viral , Conjunctivitis , Ophthalmologists , Adenoviridae Infections/drug therapy , Adrenal Cortex Hormones/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antiviral Agents/therapeutic use , Conjunctivitis/drug therapy , Conjunctivitis, Viral/drug therapy , Conjunctivitis, Viral/epidemiology , Conjunctivitis, Viral/prevention & control , Health Knowledge, Attitudes, Practice , Humans , Lubricants/therapeutic use , Ophthalmic Solutions/therapeutic use , Povidone-Iodine/therapeutic use , Surveys and Questionnaires
6.
Front Immunol ; 12: 638575, 2021.
Article in English | MEDLINE | ID: mdl-33968030

ABSTRACT

Metformin is not only the first-line medication for the treatment of type 2 diabetes, but it is also effective as an anti-inflammatory, anti-oxidative and anti-tumor agent. However, the effect of metformin during viral hepatitis remains elusive. Using an adenovirus (Ad)-induced viral hepatitis mouse model, we found that metformin treatment significantly attenuated liver injury, with reduced serum aspartate transaminase (AST) and alanine transaminase (ALT) levels and liver histological changes, presumably via decreased effector T cell responses. We then demonstrated that metformin reduced mTORC1 activity in T cells from infected mice, as evidenced by decreased phosphorylation of ribosome protein S6 (p-S6). The inhibitory effects on the mTORC1 signaling by metformin was dependent on the tuberous sclerosis complex 1 (TSC1). Mechanistically, metformin treatment modulated the phosphorylation of dynamin-related protein 1 (Drp-1) and mitochondrial fission 1 protein (FIS1), resulting in increased mass in effector T cells. Moreover, metformin treatment promoted mitochondrial superoxide production, which can inhibit excessive T cell activation in viral hepatitis. Together, our results revealed a protective role and therapeutic potential of metformin against liver injury in acute viral hepatitis via modulating effector T cell activation via regulating the mTORC1 pathway and mitochondrial functions.


Subject(s)
Adenoviridae Infections/drug therapy , Adenoviridae/physiology , Hepatitis, Viral, Animal/drug therapy , Hypoglycemic Agents/therapeutic use , Liver/pathology , Metformin/therapeutic use , Mitochondria/metabolism , Adenoviridae Infections/immunology , Animals , Cells, Cultured , Disease Models, Animal , Energy Metabolism , Female , Hepatitis, Viral, Animal/immunology , Humans , Liver/drug effects , Lymphocyte Activation , Mechanistic Target of Rapamycin Complex 1/metabolism , Mice , Mice, Inbred C57BL , Tuberous Sclerosis Complex 1 Protein/metabolism
7.
Int J Hematol ; 114(1): 109-115, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33728556

ABSTRACT

Although some studies have suggested the effectiveness of hyperbaric oxygen (HBO) therapy for hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT), the role of HBO has not been established. We compared the treatment outcomes of 8 patients with viral HC (adenovirus [ADV], n = 2; BK virus [BKV], n = 6) treated with HBO (HBO[+]) and 8 patients (ADV, n = 2; BKV, n = 6) treated with conventional therapy (HBO[-]), such as urinary catheterization and intravenous cidofovir. HBO therapy was performed at 2.1 atmospheres for 90 min/day until clinical improvement was achieved. The median number of HBO treatments was 10 (range 8-12). The median duration of HBO treatment was 19.5 days (range 10-23 days). All 8 HBO(+) patients achieved complete remission (CR) at a median of 14.5 days (range 5-25 days). Of the 8 HBO(-) patients, 5 (62.5%) obtained CR and 3 remained symptomatic for 2-6 months. The cumulative incidence of transplant-related mortality at day 100 after allogeneic HSCT was significantly higher in the HBO(-) patients than in the HBO(+) patients (14.2 vs. 0%, P < 0.05). No severe HBO-related adverse effects were observed. In conclusion, HBO is a feasible option for treating viral HC after allogeneic HSCT.


Subject(s)
Cystitis/therapy , Cystitis/virology , Hematopoietic Stem Cell Transplantation , Hemorrhage/therapy , Hemorrhage/virology , Hyperbaric Oxygenation , Adenoviridae/isolation & purification , Adenoviridae Infections/complications , Adult , BK Virus/isolation & purification , Cystitis/etiology , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Hemorrhage/etiology , Humans , Hyperbaric Oxygenation/methods , Male , Middle Aged , Polyomavirus Infections/complications , Transplantation, Homologous/adverse effects , Treatment Outcome , Young Adult
8.
Exp Clin Endocrinol Diabetes ; 129(7): 519-527, 2021 Jul.
Article in English | MEDLINE | ID: mdl-31340394

ABSTRACT

AIMS AND METHODS: The declining ability to control blood glucose with advancement of age is an important health risk factor and may lead to insulin resistance, type-2-diabetes and Alzheimer's disease. Adenovirus 36(Ad36) improves glycemic control independent of insulin signaling(insulin sparing effect) as evidenced by cell, animal and observational human studies. This property of Ad36 may be useful in correcting aging-related glucose intolerance and related health conditions. Therefore, we determined the effect of Ad36 on glycemic control in older mice, to identify the age group that best responds to Ad36. Six, 12 or 20-month old C57Bl/6 mice on chow diet were each divided into weight-matched groups(mock-infected or Ad36-infected). Body weight was recorded weekly post infection (p.i.) and fasting glucose measured(week 0, 4, 8 and 20 p.i.). Blood glucose and serum insulin were measured during glucose tolerance test(week 0 and 16 p.i.). At week 20 p.i., animals were sacrificed, blood and tissues collected. RESULTS: Mice from all age groups showed improvement in glucose clearance post Ad36 infection, but a more profound effect was observed in 6-month old mice compared with mock-infected mice. Under fed conditions though there was no difference in blood glucose at 20 wk p.i., interestingly, Ad36 reduced serum insulin in age groups old mice, compared with control mice. CONCLUSIONS: These findings suggest Ad36 infected animals improve glycemic control and clear post-prandial gluco00000se increase without increasing insulin secretion in an insulin sparing manner. These beneficial effects provide strong evidence for developing Ad36-based approaches as a novel tool to attenuate age associated glucose intolerance.


Subject(s)
Adenoviridae Infections , Aging/metabolism , Biological Therapy , Blood Glucose , Glucose Intolerance/blood , Glucose Intolerance/therapy , Insulin/blood , Age Factors , Animals , Disease Models, Animal , Male , Mice , Mice, Inbred C57BL
9.
J Gen Virol ; 101(7): 760-771, 2020 07.
Article in English | MEDLINE | ID: mdl-32459612

ABSTRACT

Turkey adenovirus 3 (TAdV-3) is the causative agent of an immune-mediated disease in turkeys, haemorrhagic enteritis, through targeting B lymphocytes. In the present study, we investigated the role of sialic acid in TAdV-3 entry and characterized the structural components of TAdV-3 receptor(s) on RP19, B lymphoblastoid cells. Removal of the cell-surface sialic acids by neuraminidases or blocking of sialic acids by wheat germ agglutinin lectin reduced virus infection. Pre-incubation of cells with Maackia amurensis lectin or Sambucus nigra agglutinin resulted in virus reduction, suggesting that TAdV-3 uses both α2,3-linked and α2,6-linked sialic acids as attachment receptor. Virus infectivity data from RP19 cells treated with sodium periodate, proteases (trypsin or bromelain) or metabolic inhibitors (dl-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, tunicamycin, or benzyl N-acetyl-α-d-galactosaminide) indicated that N-linked, but not O-linked, carbohydrates are part of the sialylated receptor and they are likely based on a membrane glycoprotein, rather than a glycolipid. Furthermore, our data, in conjunction with previous findings, implies that the secondary receptor for TAdV-3 is a protein molecule since the inhibition of glycolipid biosynthesis did not affect the virus infection, which was rather reduced by protease treatment. We can conclude that terminal sialic acids attached to N-linked membrane glycoproteins on B cells are used for virus attachment and are essential for successful virus infection.


Subject(s)
Glycoproteins/metabolism , Host-Pathogen Interactions , Receptors, Virus/metabolism , Siadenovirus/physiology , Sialic Acids/metabolism , Adenoviridae Infections/metabolism , Adenoviridae Infections/virology , Animals , Cell Line , Enzyme Activation , Flow Cytometry , Neuraminidase/metabolism , Virus Attachment , Virus Replication
10.
Ocul Surf ; 17(4): 828-832, 2019 10.
Article in English | MEDLINE | ID: mdl-31401340

ABSTRACT

PURPOSE: To report safety and tolerability of a one-time administration of ophthalmic 5% povidone-iodine (5% PVP-I) in a double-masked randomized trial for the treatment of adenoviral conjunctivitis (Ad-Cs). METHODS: Of 212 participants screened, 56 eligible participants with red eye symptoms ≤4 days and a positive adenoviral rapid immunoassay were randomized to a one-time administration of ophthalmic 5% PVP-I or preservative free artificial tears (AT). Safety was assessed by corneal fluorescein staining (baseline, immediate post-administration and Day 1) and visual acuity (VA) (baseline and Day 1). Tolerability was assessed using participant-rated overall ocular discomfort (baseline, immediately post-administration and on Day 1. RESULTS: In the 5% PVP-I group, corneal staining increased immediately post-administration but returned to baseline levels by Day 1. There was no change in VA between baseline and Day 1 in either 5% PVP-I or AT groups (p = 0.87). In the 5% PVP-I group, there was no change in participant-rated overall discomfort immediately post-administration (p = 0.78) or on day 1 (p = 0.10) compared to baseline. In the AT group, participant-rated overall discomfort was lower immediately post-administration but returned to baseline levels by Day 1. One adverse event was reported in the 5% PVP-I group on Day 1-2 that was classified as not related to treatment. CONCLUSION: These results suggest ophthalmic 5% PVP-I used as a one-time treatment is safe and well tolerated by patients with Ad-Cs.


Subject(s)
Adenoviridae Infections/drug therapy , Conjunctivitis/drug therapy , Eye Infections, Viral/drug therapy , Lubricant Eye Drops , Povidone-Iodine/administration & dosage , Visual Acuity , Adult , Conjunctivitis/virology , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Male , Retrospective Studies , Treatment Outcome
11.
Food Environ Virol ; 11(2): 157-166, 2019 06.
Article in English | MEDLINE | ID: mdl-30719622

ABSTRACT

Millions of people use contaminated water sources for direct consumption. Chlorine is the most widely disinfection product but can produce toxic by-products. In this context, natural and synthetic compounds can be an alternative to water disinfection. Therefore, the aim of this study was to assess the inactivation of human adenovirus by N-chlorotaurine (NCT), bromamine-T (BAT) and Grape seed extract (GSE) in water. Distilled water artificially contaminated with recombinant human adenovirus type 5 (rAdV-GFP) was treated with different concentrations of each compound for up to 120 min, and viral infectivity was assessed by fluorescence microscopy. The decrease in activity of the compounds in the presence of organic matter was evaluated in water supplemented with peptone. As results, NCT and GSE inactivated approximately 2.5 log10 of adenovirus after 120 min. With BAT, more than 4.0 log10 decrease was observed within 10 min. The oxidative activity of 1% BAT decreased by 50% in 0.5% peptone within a few minutes, while the reduction was only 30% for 1% NCT in 5% peptone after 60 min. Organic matter had no effect on the activity of GSE. Moreover, the minimal concentration of BAT and GSE to kill viruses was lower than that known to kill human cells. It was concluded that the three compounds have potential to be used for water disinfection for drinking or reuse purposes.


Subject(s)
Adenoviruses, Human/drug effects , Disinfectants/pharmacology , Disinfection/methods , Fresh Water/virology , Grape Seed Extract/pharmacology , Sulfonamides/pharmacology , Taurine/analogs & derivatives , Virus Inactivation/drug effects , Adenoviridae Infections/virology , Adenoviruses, Human/growth & development , Adenoviruses, Human/physiology , Humans , Taurine/pharmacology
12.
J Vet Diagn Invest ; 31(1): 78-82, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30541409

ABSTRACT

Seven colostrum-deprived, 3-4-wk-old Rambouillet-Hampshire lambs were inoculated via the mucous membranes with deer adenovirus (DAdV) and monitored for clinical signs for 21 d post-inoculation at which time animals were euthanized and postmortem examinations were performed. Pre-inoculation and post-inoculation serum samples were tested for antibodies to DAdV, ovine adenovirus 7, bovine adenovirus 7, and goat adenovirus 1. Evidence for DAdV infection was determined by virus isolation, PCR tests, and histopathology with immunohistochemistry tests for DAdV. No clinical signs or lesions consistent with adenoviral hemorrhagic disease (AHD) in deer were seen in the lambs, and the lambs did not seroconvert to DAdV. DAdV was not detected by PCR, virus isolation, or immunohistochemistry in any of the samples tested from the lambs. A positive control deer similarly inoculated with DAdV developed fatal AHD 1 wk post-inoculation. Our colostrum-deprived lambs did not become infected when inoculated with DAdV.


Subject(s)
Adenoviridae Infections/veterinary , Atadenovirus/isolation & purification , Colostrum/immunology , Sheep Diseases/virology , Adenoviridae Infections/immunology , Animals , Animals, Domestic , Animals, Newborn , Animals, Suckling , Atadenovirus/immunology , Female , Immunohistochemistry/veterinary , Polymerase Chain Reaction/veterinary , Pregnancy , Sheep , Sheep Diseases/immunology
13.
BMC Vet Res ; 14(1): 404, 2018 Dec 17.
Article in English | MEDLINE | ID: mdl-30558623

ABSTRACT

BACKGROUND: The results of experiments involving broiler chickens and turkeys indicate that increased dietary methionine (Met) levels may improve the antioxidant protection of tissues in fast-growing birds. This is an important consideration since viral infections induce oxidative stress. The aim of this study was to verify the hypothesis that turkey diets with increased Met content can suppress oxidation processes induced by infection caused by the haemorrhagic enteritis virus (HEV), and that the noted effect is determined by the chemical form of this amino acid: DL-methionine (DLM) or DL-hydroxy analogue of Met (MHA). RESULTS: Dietary Met content above 40% higher than the level recommended by the NRC (1994) intensified lipid peroxidation in the small intestine, leading to an increase in malondialdehyde (MDA) and lipid peroxide (LOOH) levels, but it also stimulated antioxidant mechanisms in the blood and liver of turkeys infected with HEV. In comparison with DLM, MHA contributed to more severe symptoms of oxidative stress, such as elevated MDA levels in the intestines, and a decrease in glutathione peroxidase (GPx) activity and ferric-reducing ability of plasma (FRAP). CONCLUSIONS: In HEV-infected turkeys, diets with increased Met content did not exert a clear antioxidant effect, which was noted in uninfected birds. The prooxidant activity of Met observed in the small intestinal wall was suppressed in the blood and liver of turkeys, most likely due to intensified synthesis of uric acid and glutathione. In comparison with MHA, DLM had a more beneficial influence on the analysed parameters of the redox status in the small intestine, blood and liver of turkeys.


Subject(s)
Adenoviridae Infections/veterinary , Animal Nutritional Physiological Phenomena , Diet/veterinary , Dietary Supplements , Oxidative Stress/physiology , Poultry Diseases/physiopathology , Turkeys/physiology , Adenoviridae Infections/physiopathology , Animals , Methionine/administration & dosage , Siadenovirus
14.
PLoS One ; 13(10): e0200043, 2018.
Article in English | MEDLINE | ID: mdl-30332435

ABSTRACT

Infection of immunocompromised individuals with normally benign opportunistic viruses is a major health burden globally. Infections with viruses such as Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), Kaposi's sarcoma virus (KSHV), adenoviruses (AdV), BK virus (BKPyV), John Cunningham virus (JCPyV), and human papillomavirus (HPV) are significant concerns for the immunocompromised, including when these viruses exist as a co-infection with human immunodeficiency virus (HIV). These viral infections are more complicated in patients with a weakened immune system, and often manifest as malignancies resulting in significant morbidity and mortality. Vaccination is not an attractive option for these immune compromised individuals due to defects in their adaptive immune response. Verdinexor is part of a novel class of small molecules known as SINE (Selective Inhibitor of Nuclear Export) compounds. These small molecules demonstrate specificity for the nuclear export protein XPO1, to which they bind and block function, resulting in sequestration of XPO1-dependent proteins in the nucleus of the cell. In antiviral screening, verdinexor demonstrated varying levels of efficacy against all of the aforementioned viruses including previously with HIV. Studies by other labs have discussed likely mechanisms of action for verdinexor (ie. XPO1-dependence) against each virus. GLP toxicology studies suggest that anti-viral activity can be achieved at a tolerable dose range, based on the safety profile of a previous phase 1 clinical trial of verdinexor in healthy human volunteers. Taken together, these results indicate verdinexor has the potential to be a broad spectrum antiviral for immunocompromised subjects for which vaccination is a poor option.


Subject(s)
Acrylamides/pharmacology , Hydrazines/pharmacology , Immunocompromised Host/drug effects , Karyopherins/antagonists & inhibitors , Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors , Virus Diseases/drug therapy , Adenoviridae Infections/drug therapy , Animals , Cell Line, Tumor , Cytomegalovirus Infections/drug therapy , Drug Evaluation, Preclinical , Epstein-Barr Virus Infections/drug therapy , Fibroblasts/virology , Guinea Pigs , HEK293 Cells , HIV Infections/complications , HeLa Cells , Humans , Mice , Papillomavirus Infections/drug therapy , Polyomavirus Infections/drug therapy , Reproducibility of Results , Sarcoma, Kaposi/drug therapy , Tumor Virus Infections/drug therapy , Virus Diseases/complications , Exportin 1 Protein
15.
Sci Rep ; 7(1): 3697, 2017 06 16.
Article in English | MEDLINE | ID: mdl-28623340

ABSTRACT

Glucokinase (GK), the hexokinase involved in glucosensing in pancreatic ß-cells, is also expressed in arcuate nucleus (AN) neurons and hypothalamic tanycytes, the cells that surround the basal third ventricle (3V). Several lines of evidence suggest that tanycytes may be involved in the regulation of energy homeostasis. Tanycytes have extended cell processes that contact the feeding-regulating neurons in the AN, particularly, agouti-related protein (AgRP), neuropeptide Y (NPY), cocaine- and amphetamine-regulated transcript (CART) and proopiomelanocortin (POMC) neurons. In this study, we developed an adenovirus expressing GK shRNA to inhibit GK expression in vivo. When injected into the 3V of rats, this adenovirus preferentially transduced tanycytes. qRT-PCR and Western blot assays confirmed GK mRNA and protein levels were lower in GK knockdown animals compared to the controls. In response to an intracerebroventricular glucose injection, the mRNA levels of anorexigenic POMC and CART and orexigenic AgRP and NPY neuropeptides were altered in GK knockdown animals. Similarly, food intake, meal duration, frequency of eating events and the cumulative eating time were increased, whereas the intervals between meals were decreased in GK knockdown rats, suggesting a decrease in satiety. Thus, GK expression in the ventricular cells appears to play an important role in feeding behavior.


Subject(s)
Adenoviridae/physiology , Feeding Behavior , Glucokinase/metabolism , Hypothalamus/metabolism , Hypothalamus/physiopathology , Adenoviridae Infections , Animals , Encephalitis/etiology , Encephalitis/metabolism , Encephalitis/pathology , Gene Expression , Gene Expression Regulation , Genes, Reporter , Hypothalamus/pathology , Hypothalamus/virology , Male , Neuropeptides/genetics , Neuropeptides/metabolism , Rats , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism
16.
Eye Contact Lens ; 42(6): 388-391, 2016 11.
Article in English | MEDLINE | ID: mdl-26671622

ABSTRACT

PURPOSE: To evaluate the safety and efficacy of the use of the bandage contact lenses (BCLs) in adenoviral keratoconjunctivitis-related ocular surface problems. METHODS: Fifteen eyes of 15 consecutive patients presenting at the Ankara University Medical Center, Cornea and Contact Lens Service, and requiring BCL use for adenoviral keratoconjunctivitis-related ocular surface problems were enrolled. Visual acuity, slitlamp examination findings, indication and duration of the BCL use, the total follow-up, and any adjuvant medication were recorded. All patients were followed regarding the success of treatment and adverse effects associated with BCL use. RESULTS: The average age at the time of presentation was 26.8±15.5 years. The major reasons for BCL use included epithelial defect (7 eyes), filamentous keratopathy (5 eyes), epithelial edema (1 eyes), and filamentous keratopathy together with epithelial defect (2 eyes). After the first appearance of conjunctivitis symptoms, the mean time to BCL application was 9.0±3.9 days. The mean duration of contact lens wear was 9.9±6.5 days, and the mean follow-up was 26.4±15.8 days. Preservative-free artificial tears and topical antibiotics were used in all cases. Besides, topical ganciclovir 0.15% gel (8 eyes), topical 0.4% povidone-iodine solution (9 eyes), and topical steroids (11 eyes) were used in various combinations. At the end of the follow-up period, the mean visual acuity improved from 0.23±0.32 logMAR units (∼0.6 Snellen line) to 0.0l±0.04 logMAR units (∼1.0 Snellen line) (P=0.042). No sight-threatening complication related to contact lens wear was encountered. CONCLUSION: Adjuvant use of BCLs seems to be safe and effective in the treatment of adenoviral keratoconjunctivitis-related ocular surface problems. Close follow-up and prophylactic use of topical antibiotics are rationalistic for prevention of secondary infections.


Subject(s)
Adenoviridae Infections/therapy , Bandages , Contact Lenses, Hydrophilic , Eye Infections, Viral/therapy , Keratoconjunctivitis/therapy , Keratoconjunctivitis/virology , Adenoviridae Infections/complications , Adolescent , Adult , Child , Child, Preschool , Eye Infections, Viral/complications , Female , Ganciclovir/therapeutic use , Humans , Lubricant Eye Drops/therapeutic use , Male , Middle Aged , Visual Acuity , Young Adult
17.
Microbiol Immunol ; 58(5): 303-6, 2014 May.
Article in English | MEDLINE | ID: mdl-24580367

ABSTRACT

Adenovirus 36 (Ad36) is known to be associated with human obesity and to trigger inflammation in murine models. However, to date no clinical drugs for treating virus-induced obesity have been developed. Therefore, in this study, the anti-obesity and anti-inflammation effects of mulberry extract on Ad36 were evaluated in mice. The mulberry extract-fed group showed a reduction in total body weight and in epidermal fat pads. A combination of various mulberry components (1-deoxynojirimycin, kuromanin chloride and resveratrol) and a mulberry extract prevented viral replication by 50% and 70%, respectively, compared with an untreated Ad36-infected group. Moreover, the extract decreased both concentrations of proinflammatory cytokines, such as MCP-1 and TNF-α, and the numbers of infiltrating immune cells and macrophages in epidermal fat pads. In conclusion, dietary mulberry extract might offer an avenue for the development of therapeutic approaches for treating or preventing virus-induced obesity and inflammation-related metabolic diseases.


Subject(s)
Adenoviridae Infections/drug therapy , Adenoviruses, Human/drug effects , Antiviral Agents/therapeutic use , Morus/chemistry , Obesity/prevention & control , Plant Extracts/therapeutic use , Adenoviridae Infections/complications , Adenoviruses, Human/physiology , Animals , Antiviral Agents/isolation & purification , Cytokines/metabolism , Disease Models, Animal , Inflammation/prevention & control , Leukocytes/immunology , Mice , Plant Extracts/isolation & purification , Skin/pathology , Virus Replication/drug effects
18.
J Pharm Pharmacol ; 63(5): 688-94, 2011 May.
Article in English | MEDLINE | ID: mdl-21492171

ABSTRACT

OBJECTIVES: Astragaloside IV, purified from the Chinese medical herb Astragalus membranaceus (Fisch) Bge and Astragalus caspicus Bieb, is an important natural product with multiple pharmacological actions. This study investigated the anti-ADVs effect of astragaloside IV on HAdV-3 (human adenovirus type 3) in A549 cell. METHODS: CPE, MTT, quantitative real-time PCR (qPCR), flow cytometry (FCM) and Western blot were apply to detect the cytotoxicity, the inhibition and the mechanisms of astragaloside IV on HAdV-3. KEY FINDINGS: TC(0 ) of astragaloside IV was 116.8 µm, the virus inhibition rate from 15.98% to 65.68% positively was correlated with the concentration of astragaloside IV from 1.25 µm to 80 µm, IC50 (the medium inhibitory concentration) was 23.85 µm, LC50 (lethal dose 50% concentration) was 865.26 µm and the TI (therapeutic index) was 36.28. qPCR result showed astragaloside IV inhibited the replication of HAdV-3. Flow FCM analysis demonstrated that the anti-HAdV-3 effect was associated with apoptosis. Astragaloside IV was further detected to reduce the protein expressions of Bax and Caspase-3 and increasing the protein expressions of Bcl-2 using western blotting, which improved the anti-apoptosis mechanism of astragaloside IV on HAdV-3. CONCLUSIONS: Our findings suggested that astragaloside IV possessed anti-HAdV-3 capabilities and the underlying mechanisms might involve inhibiting HAdV-3 replication and HAdV-3-induced apoptosis.


Subject(s)
Adenoviridae Infections/drug therapy , Adenoviridae/drug effects , Antiviral Agents/pharmacology , Apoptosis/drug effects , Astragalus propinquus/chemistry , Phytotherapy , Saponins/pharmacology , Triterpenes/pharmacology , Adenoviridae/pathogenicity , Adenoviridae/physiology , Adenoviridae Infections/metabolism , Caspase 3/metabolism , Cell Line , Humans , Inhibitory Concentration 50 , Plant Extracts/chemistry , Plant Extracts/pharmacology , Virus Replication/drug effects , bcl-2-Associated X Protein/metabolism
19.
Biol Pharm Bull ; 34(2): 197-202, 2011.
Article in English | MEDLINE | ID: mdl-21415527

ABSTRACT

Radix Lithosperm eyrthrorhizon is a common prescription compound in traditional Chinese medicine. Shikonin is a major component of Radix Lithospermi and has various biological activities. We have investigated the inhibitory effect of shikonin on the growth of adenovirus type 3 (AdV3) in vitro. The antiviral function of shikonin against AdV3 and its virus inhibition ratio were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method (MTT). The expression of hexon protein in AdV3 was determined by immunofluorescence assay using laser scanning confocal microscopy (LSCM) and Western blot analysis. In addition, the rate of apoptosis in cells infected by AdV3 was determined by flow cytometry. Shikonin (0.0156-1 µM) inhibited growth of AdV3 in a concentration-dependent manner with a virus inhibition rate of 23.8-69.1%. Expression of hexon protein in AdV3 was higher in the virus control group than in the shikonin-treated groups as determined by immunofluorescence assay and Western blotting (p<0.05). The rate of shikonin-treated HeLa cell apoptosis had a statistically significant decrease with increasing concentration of drug (p<0.05). Our data demonstrate that shikonin possesses anti-AdV3 capabilities and that the potential antiviral mechanism might involve inhibiting the degree of apoptosis and hexon protein expression of AdV.


Subject(s)
Adenoviridae Infections/drug therapy , Adenoviridae/drug effects , Antiviral Agents/pharmacology , Capsid Proteins/metabolism , Drugs, Chinese Herbal/pharmacology , Lithospermum/chemistry , Naphthoquinones/pharmacology , Adenoviridae/growth & development , Antiviral Agents/therapeutic use , Apoptosis/drug effects , Dose-Response Relationship, Drug , Drugs, Chinese Herbal/therapeutic use , HeLa Cells , Humans , Naphthoquinones/therapeutic use , Phytotherapy , Plant Roots
20.
J Ethnopharmacol ; 134(2): 468-74, 2011 Mar 24.
Article in English | MEDLINE | ID: mdl-21211557

ABSTRACT

AIM OF THE STUDY: Extracts from the aerial parts of the South African resurrection plant Myrothamnus flabellifolia Welw. have been used traditionally against infections of the upper respiratory tract and skin diseases. A polyphenol-enriched extract was investigated for potential antiviral effects against herpes simplex virus type 1 (HSV-1) and adenovirus, and the underlying mode of action was to be studied. MATERIALS AND METHODS: Antiviral effects of an acetone-water extract (MF) from Myrothamnus flabellifolia on HSV-1 and adenovirus type 3 were tested in infected Vero cells by plaque reduction assay, MTT test and immunofluorescence. The influence of the extract on the HSV-1 envelope glycoprotein D was shown by Western blot. Organotypic full thickness skin models consisting of multilayer skin equivalents were used for the investigation of MF effects on HSV-1 replication. RESULTS: MF exhibited strong antiviral activity against HSV-1. The HSV-1-specific inhibitory concentration (IC(50)) was determined as 0.4 µg/mL and the cytotoxic concentration (CC(50)) against Vero cells as 50 µg/mL. A selectivity index (SI) (ratio of CC(50) to IC(50)) of approximately 120 was calculated when MF was added to the virus inoculum for 1h at 37°C prior to infection. The replication of adenovirus 3 was not affected by MF. MF abolished virus entry into the host cell by blocking viral attachment to the cell surface. When added after attachment at a concentration of >6 µg/mL, the extract also inhibited penetration of HSV-1 into the host cell. Polyphenolic compounds from MF directly interacted with viral particles, leading to the oligomerisation of envelope proteins as demonstrated for the essential viral glycoprotein D (gD). Using organotypic full thickness tissue cultures, it was shown that treatment of HSV-1 infected cultures with the MF resulted in reduced viral spread. CONCLUSIONS: A polyphenol-enriched extract from Myrothamnus flabellifolia strongly acts against HSV-1 by blocking viral entry into the cells.


Subject(s)
Antiviral Agents/therapeutic use , Herpes Simplex/drug therapy , Herpesvirus 1, Human/drug effects , Magnoliopsida/chemistry , Phytotherapy , Plant Extracts/therapeutic use , Proanthocyanidins/therapeutic use , Adenoviridae/drug effects , Adenoviridae Infections/microbiology , Animals , Antiviral Agents/pharmacology , Cell Line , Chlorocebus aethiops , Herpes Simplex/microbiology , Herpesvirus 1, Human/chemistry , Herpesvirus 1, Human/pathogenicity , Humans , Inhibitory Concentration 50 , Keratinocytes/drug effects , Keratinocytes/microbiology , Plant Components, Aerial , Plant Extracts/pharmacology , Proanthocyanidins/pharmacology , Skin/drug effects , Skin/microbiology , Vero Cells , Viral Envelope Proteins/chemistry , Virus Integration/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL